Is CLDX or ICCC more undervalued in 2026?

CirclFi compares Celldex Therapeutics, Inc. (CLDX) and ImmuCell Corporation (ICCC) using 13 institutional-grade valuation models. CLDX has a Quality of Company score of 5.6/10 while ICCC scores 7.0/10.

Which is a better buy — CLDX or ICCC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CLDX and ICCC valuations compare?

CLDX at $31.43 and ICCC at $10.24 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CLDX vs ICCC Valuation Comparison 2026 — Intrinsic Value Analysis

CLDX

In Vitro & In Vivo Diagnostic Substances

Celldex Therapeutics, Inc.

Quality

5.6

out of 10

Value Trap

WARN

Price

$31.43

Last close

Models

12/13

Active

ICCC

In Vitro & In Vivo Diagnostic Substances

ImmuCell Corporation

Quality

7.0

out of 10

Value Trap

SAFE

Price

$10.24

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CLDX Fair Value	CLDX Upside	ICCC Fair Value	ICCC Upside
Bayesian DCF	Intrinsic	$9.47	-69.9%	$1.08	-89.4%
Earnings Power Value	Intrinsic	$1.05	-96.8%	$5.11	-50.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLDX vs ICCC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLDX vs ICCC — Which Stock Is More Undervalued?

ICCC scores higher with a 7.0/10 quality rating vs CLDX's 5.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Celldex Therapeutics, Inc. (CLDX) and ImmuCell Corporation (ICCC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLDX currently trades at $31.43 with a QOC of 5.6/10, while ICCC trades at $10.24 with a QOC of 7.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).